These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 25342291)

  • 1. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
    Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed methotrexate excretion in infants and young children with central nervous system tumors and postoperative fluid collections.
    Cohen I
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):875. PubMed ID: 25672914
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to: comment on "Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections".
    Wright KD; Stewart CF
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):877-8. PubMed ID: 25711766
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of malignant effusions on methotrexate disposition.
    Li J; Gwilt P
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):373-82. PubMed ID: 12439595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors.
    Lucchesi M; Guidi M; Fonte C; Farina S; Fiorini P; Favre C; de Martino M; Sardi I
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):857-64. PubMed ID: 26988222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
    Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
    Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours.
    Panetta JC; Roberts JK; Huang J; Lin T; Daryani VM; Harstead KE; Patel YT; Onar-Thomas A; Campagne O; Ward DA; Broniscer A; Robinson G; Gajjar A; Stewart CF
    Br J Clin Pharmacol; 2020 Feb; 86(2):362-371. PubMed ID: 31657864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.
    Dombrowsky E; Jayaraman B; Narayan M; Barrett JS
    Ther Drug Monit; 2011 Feb; 33(1):99-107. PubMed ID: 21192315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity profile of high-dose methotrexate in young children with central nervous system tumors.
    Chavana AN; Taylor ZL; DeGroote N; Lindsay HB; Sauer HE; Mason EJ; Schafer ES; Miller TP; Castellino SM; Pommert L; O'Brien MM; Ramsey LB; Bernhardt MB; Brown AL
    Pediatr Blood Cancer; 2024 Oct; 71(10):e31213. PubMed ID: 39039774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.
    Nathan PC; Maze R; Spiegler B; Greenberg ML; Weitzman S; Hitzler JK
    Pediatr Blood Cancer; 2004 Jan; 42(1):24-9. PubMed ID: 14752790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxypeptidase G2 rescue after high-dose methotrexate.
    DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
    J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
    Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.